Verily and Samsung announced a partnership to integrate Galaxy smartwatch data into Verily’s Pre platform, creating an end‑to‑end solution for deploying wearables in clinical trials and analyzing remote patient data. The collaboration aims to streamline device provisioning, data ingestion, and downstream analytics to support decentralized and hybrid trials. Medtech and pharma sponsors stand to gain standardized wearable data capture that reduces site burden and improves longitudinal monitoring of activity, vitals, and digital endpoints. The integration could lower barriers for sponsors to adopt continuous digital biomarkers in registrational studies, contingent on validation and regulatory acceptance of wearable‑derived endpoints.